How Five Structural Forces Are Reshaping the Global Medtech Industry

Executive Summary

The global medical technology (medtech) industry stands at a critical inflection point. As 2026 approaches, five structural forces are converging to rewrite the rules of competitive advantage: Mainland China’s evolving volume-based procurement (VBP) program, the continued migration of procedures to outpatient settings, persistent global trade and supply chain pressures, the clinical and commercial impact of GLP-1 receptor agonists, and the rise of platform-based competition powered by enabling technologies. For executives and investors, understanding these forces is no longer optional—they are reshaping market economics, operational strategies, and the very definition of value in healthcare.

Introduction

The medtech sector has long been characterized by steady innovation cycles, regulatory complexity, and resilient demand. Yet the current environment is different. A confluence of policy, technology, and demographic shifts is compressing traditional margins, opening new care settings, and demanding new forms of organizational agility. Clarivate’s Medtech Trends to Watch 2026 report provides proprietary data and expert analysis on these dynamics. This article distills the strategic essence of those findings, framing the trends for business leaders operating in global markets.

Market Context

Medical technology remains one of the most dynamic sectors in global commerce. Annual revenue exceeds $500 billion, with growth supported by aging populations, rising chronic disease burdens, and continuous innovation in diagnostics, devices, and digital health. However, the competitive landscape has become more unforgiving. Pricing pressures, regulatory scrutiny, and expectations of value-based care are forcing companies to evolve from product-centric models to solutions-oriented, data-driven strategies. The five trends outlined below are not isolated phenomena; they are interconnected forces that compound each other’s effects.

Main Analysis

1. Mainland China’s VBP Expansion: A New Global Pricing Benchmark

Mainland China’s national volume-based procurement (VBP) program has evolved from a patient-access initiative into a powerful market-structuring mechanism. The latest round introduces more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. For multinational companies, VBP is no longer a localized policy issue. It sets expectations for price, volume, and competitive positioning in other markets, particularly in emerging economies where Chinese products and pricing models increasingly set reference points.

The strategic implication is profound: medtech companies must redesign portfolio strategies to survive in China while leveraging that experience to compete elsewhere. Domestic innovation is accelerating as local firms use VBP-driven scale to invest in R&D, further intensifying competitive pressure.

2. The Shift to Outpatient and Ambulatory Surgical Centers

The migration of procedures from hospitals to outpatient settings, particularly ambulatory surgical centers (ASCs), is accelerating. The U.S. Centers for Medicare & Medicaid Services’ 2026 rules expand the ASC Covered Procedure List and phase out the inpatient-only list, enabling higher-acuity procedures like cardiac ablation to move to lower-cost environments. This is a continuation of broader trends across orthopedics, general surgery, and other specialties.

For medtech manufacturers, this shift alters the commercial equation. ASCs demand different value propositions, simpler product designs, and economic models that emphasize efficiency and rapid turnover. Companies that treat ASCs as a secondary channel will miss growth opportunities; those that integrate them into core strategy will capture early-mover advantages.

3. Trade and Supply Chain Pressures: From Just-in-Time to Just-in-Case

Global trade tensions, tariffs, and fluctuating material costs have exposed the fragility of concentrated supply chains. Medtech companies are responding by diversifying suppliers, building multi-region manufacturing footprints, and investing in resilience. Scale is becoming an advantage, as larger firms buffer against volatility through vertical integration and technology investment. This trend is reshaping cost structures and competitive dynamics across categories.

For executives, the lesson is clear: supply chain resilience now determines market competitiveness as much as product performance. Tariff exposure and geopolitical risk must be factored into every manufacturing and sourcing decision.

4. GLP-1 Therapies: Reshaping Patient Behavior and Care Pathways

The explosive adoption of GLP-1 receptor agonists for weight management and metabolic disease is altering patient and clinician behavior with ripple effects across medtech. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1s are changing referral patterns. Some bariatric procedures are experiencing volume pressure, while adjacent categories—diabetes care, sleep apnea, cardiovascular monitoring—are seeing emerging demand shifts.

The impact is uneven and evolving. Medtech companies must monitor these dynamics closely, adjusting pipeline priorities and commercial strategies to align with a transformed metabolic disease management landscape.

5. Platform-Based Competition: The Rise of Integrated Ecosystems

Enabling technologies—robotics, imaging, navigation, digital workflow software—are no longer adjuncts to procedures. They are becoming the centerpiece of integrated platforms that span clinical planning, surgical execution, and postoperative care. Companies are investing heavily in platform architectures that anchor service lines, deepen customer relationships, and unlock data-driven value propositions. Open-platform systems are also emerging, introducing new flexibility and new competitive threats.

This shift redefines value creation. The winner is not necessarily the device with the best clinical outcome alone, but the company that orchestrates the most seamless, data-rich ecosystem. Strategy must shift from product differentiation to ecosystem leadership.

Business Impact

Each of these trends has direct commercial implications:

• Corporate Strategy: Portfolio decisions must account for VBP-driven pricing in China and the global reference effect. \- Manufacturing: Supply chain resilience becomes a source of competitive advantage; multi-region footprints are essential. \- Consumer Markets: GLP-1 adoption is changing patient demand and creating new market adjacencies. \- Innovation: Platform-based competition demands investment in software, data analytics, and partnerships. \- Trade: Tariff exposure and geopolitical risk require continuous scenario planning and agile sourcing.

Executive Insights

For C-suite leaders, the strategic imperatives are clear:

• Reassess China strategy beyond volume—focus on how VBP-informed capabilities can be leveraged in other emerging markets.
• Restructure commercial models to serve ASCs and outpatient settings with tailored value propositions and cost structures.
• Embed supply chain resilience at the board level, treating it as a strategic function, not a logistics function.
• Monitor the GLP-1 effect with granular data, distinguishing between short-term volume shifts and long-term structural changes in metabolic care.
• Invest in platform architectures that integrate devices, data, and digital workflows, either through internal development or strategic partnerships.

Future Outlook

Looking ahead to 2030, several trajectories are likely. China’s medtech market will continue to grow, but its domestic industry will become a formidable global competitor, exporting cost-effective innovation. Outpatient care will dominate many procedure categories, requiring fundamentally different product designs and service models. Supply chains will be regionalized and digitized, with real-time tracking and predictive analytics reducing risk.

GLP-1 therapies will continue to evolve, potentially expanding into novel indications and combination therapies, with unpredictable effects on device markets. Meanwhile, platform-based competition will intensify, leading to consolidation as companies seek scale in data, software, and ecosystem breadth. Open standards and AI-driven workflows will lower barriers to entry, enabling new entrants to challenge incumbents.

The most successful medtech companies will be those that embrace these structural shifts as opportunities rather than threats. They will invest in scenario planning, organizational agility, and cross-sector collaboration to stay ahead of the curve.

Conclusion

The medtech industry is not merely experiencing cyclical change; it is undergoing a structural transformation. The five trends identified by Clarivate’s Medtech Trends to Watch 2026 represent forces that will shape the industry for years. For business leaders, the imperative is to move beyond observation and take decisive action. Those who adapt their strategies, operations, and value propositions to these new realities will define the future of healthcare commerce. Those who hesitate risk being left behind in an increasingly complex, competitive, and connected global market.